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Quality of life (QoL) is an increasingly important parameter in clinical practice as it predicts
mortality and poor health outcomes. It is hypothesized that one may have a genetic predis-
position for QoL. We therefore related 139 candidate genes, selected through a literature
search, to QoL in healthy females.
Methods
In 5,142 healthy females, background characteristics (i.e. demographic, clinical, lifestyle,
and psychological factors) were assessed. QoL was measured by the EORTC QLQ-C30,
which consists of 15 domains. For all women genotype information was available. For each
candidate gene, single nucleotide polymorphisms (SNPs) were identified based on their
functional (n = 2,663) and physical annotation (n = 10,649). SNPs were related to each
QoL-domain, while controlling for background characteristics and population stratification.
Finally, gene-based analyses were performed relating the combined effect of 10,649 SNPs
(selected based on physical annotation) for each gene, to QoL using the statistical software
package VEGAS.
Results
Overall, we found no relation between genetic variations (SNPs and genes) and 14 out of
15 QoL-domains. The strongest association was found between cognitive functioning and
the top SNP rs1468951 (p = 1.21E-05) in the GSTZ1 gene. Furthermore, results of the
gene-based test showed that the combined effect of 11 SNPs within the GSTZ1 gene is sig-
nificantly associated with cognitive functioning (p = 2.60E-05).
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Conclusion
If validated, the involvement of GSTZ1 in cognitive functioning underscores its heritability
which is likely the result of differences in the dopamine pathway, as GSTZ1 contributes to
the equilibrium between dopamine and its neurotoxic metabolites via the glutathione
redox cycle.
Introduction
During the last decades quality of life (QoL) is frequently measured as a subjective rating in re-
search and clinical practice. It is a multifactorial concept that consists of a person’s perception
of physical, psychological, and social functioning that is often subdivided into several domains
(e.g. physical functioning, emotional functioning, cognitive functioning, social functioning, fa-
tigue, and pain).[1] QoL is an increasingly important parameter in both research and clinical
practice as it is predictive of mortality and poor health outcomes, such as morbidity, self-
management, and health care.[2–4]
QoL is influenced by demographic characteristics (e.g. age, sex, and race), lifestyle factors
(e.g. diet and physical activity) and psychological factors, such as mood states and stress.[5–8]
A large proportion of variation between individuals remains unexplained. It is therefore sug-
gested that individual genetic predisposition contributes to the perception of QoL.[9] There is
increasing evidence for genetic determinants of depression, well-being, pain, and fatigue.
[10–14] In addition, family and twin-studies indicate that the heritability for subjective well-
being, depression, and anxiety ranges from thirty to as much as fifty percent.[15–19] Moreover,
there is ample evidence that the hypothalamic-pituitary-adrenal axis, immune, neuroendo-
crine, and cardiovascular system are associated with various QoL-domains.[20]
In 2009 an international and interdisciplinary Consortium for Genetics and Quality of Life
Research (GeneQol) was initiated.[9] Its main objective is to identify and investigate potential
biological mechanisms, genes and genetic variants involved in QoL. The first studies relating
genes to QoL have shown that various single nucleotide polymorphisms (SNPs) in cytokine
genes and the glutathione metabolic pathway are related to QoL in different patient groups.
[21–23] The previous studies are valuable with little generalizability, as they all include only pa-
tient samples. The current study is conducted in a sample of healthy women, which increases
the generalizability, as the relation between genetics and QoL is examined without the con-
founding role of diseases. Recently, the GeneQol consortium has provided an overview of bio-
logical markers involved in overall QoL and related domains, such as fatigue, pain, negative
and positive functioning.[24] They have identified several candidate genes based on an exten-
sive literature search.[24] We aim to perform an empirical study relating these candidate genes
to QoL in a healthy female sample.
The specific objectives are (1) to relate SNPs for each of the listed candidate genes to QoL;
and (2) to relate the combined effect of SNPs within each gene to QoL.
Methods
Study population and procedure
This study utilized data from the Karolinska Mammography Project for Risk Prediction of
Breast Cancer (KARMA) study, see www.karmastudy.org for a detailed description. Data used
in this manuscript is available upon request through the KARMA Research Platform which
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can be found at www.karmastudy.org. In short, KARMA collects data and bio-samples each
time a participating woman comes for mammography screening or a clinical mammography at
one of four Swedish participating hospitals. In Sweden, the national screening program invites
all women at 18 month intervals for those 40–55 years, and for those older than 56–74 years at
24 months. Every woman completes a comprehensive online survey. This survey entails more
than 250 questions addressing breast cancer related issues such as reproductive history, cancer
treatment, and family history of cancer; lifestyle factors (e.g. alcohol and tobacco use); previous
medical conditions other than breast cancer; medication use; and QoL. Blood is donated at
each visit and processed at the Karolinska biobank. Every six months data from several regis-
tries are linked to the KARMA data: the information network for cancer treatment which en-
tails clinical information on breast cancer patients; the Swedish Cancer; Cause-of-Death;
Prescription; and In- and Out-patient registers. The KARMA study was approved by the Swed-
ish regional ethical board at the Karolinska Institutet and is conducted in accordance with the
Declaration of Helskini.[25] All women gave written informed consent.
Measurements
Background characteristics. Demographic and clinical factors All women reported age, educa-
tional level, use of painkillers (e.g. paracetamol and ibuprofen) and being on hormone replace-
ment therapy (yes/no) during the last year. Participants’ previous or ongoing medical
conditions such as, high blood pressure, hyperlipidemia, myocardial infarction, angina, heart
failure, stroke, polycystics ovary syndrome (PCOS), pre-eclampsia, depression, diabetes, bu-
limia, and anorexia were self-reported.
Life style factors BodyMass Index (BMI) was calculated based on women’s weight in kilogram
divided by their squared height in meters. Current tobacco use (yes/no) was self-reported—if
women either smoked cigarettes or used snuff (a typical Swedish tobacco in moist powder form).
Psychological factors The level of stress experienced during the last five years was assessed
by one item “Please state how stressed you have been feeling in the past five years”. Answers
could be given on a 4 point Likert-scale ranging from ‘never stressed’ to ‘always stressed’. All
participants were asked whether they have experienced any of the following life stressors dur-
ing the last five years: a close relative who died; own divorce or separation; a close friend who
died; serious disease or injury; became unemployed; other very stressing event. Finally, the av-
erage number of hours of sleep per night was assessed.
Quality of life. QoL was measured with the European Organization for Research and Treat-
ment of Cancer Quality of Life questionnaire Core 30 (EORTC QLQ-C30), a cancer specific
QoL-questionnaire.[26] It includes global health status, five functional scales (physical; role;
emotional; cognitive; and social), three symptom scales (fatigue; nausea or vomiting; and pain),
and six single items (dyspnea; insomnia; appetite loss; constipation; diarrhea; and financial dif-
ficulties). These scales and items are linearly transformed from 0 to 100. High scores on the
global health status/QoL scale indicate a high level of QoL, and high scores on the functional
scales indicate a high level of functioning. Conversely, high scores on the symptom scales/
items indicate high levels of health problems. The EORTC QLQ-C30 has been validated and is
considered to have good psychometric properties.[26]
Genotyping. Some of the KARMA participants were genotyped as part of the iCOGS proj-
ect (www.nature.com/iCOGS) using the iCOGS array. This array was specifically designed to
evaluate genetic variants associated with the risk of breast, ovarian and prostate cancer.[27,28]
It comprises ~200,000 SNPs, which were selected in samples from large case-control studies in
disease-based consortia. A genome-wide imputation of SNPs using the IMPUTE (V.2.0) soft-
ware, based on the 1000 Genomes Project [(1KGP) Mar 2012 release (updated Apr 19, 2012)],
The Genetic Basis of Quality of Life: A Candidate Gene Approach
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was performed.[29] For the KARMA dataset, the genotypes of 4,310,392 SNPs were successful-
ly called and passed quality control filter (INFO score from IMPUTE> = 0.8 and minor allele
frequency> = 0.01). The imputed iCOGS chip has a 60% coverage of what the Illumnia
HumanHap550 chip would cover.
Selection of single nucleotide polymorphisms The list of candidate genes derived by the Gene-
Qol consortium is continuously updated based on current literature.[24] At the start of this
study, the list entailed 139 candidate genes, which were all related to at least one QoL-domain
(S1 Table: The list of 139 candidate genes, which are all related to at least one QoL-domain).
SNPs for each candidate gene were selected based on both functional and physical annotation
(build 37).[30] For the functional annotation, SNPs were selected according to their effects on
expression levels, i.e. whether they are expressions of quantitative trait loci (eQTLs) for that
gene. Based on the functional annotation 2,663 SNPs were selected for the 139 candidate genes.
For the physical-based annotation, a 20 kb window was used where SNPs were categorized
based on both their position and linkage disequilibrium (LD) pattern. For the 139 candidate
genes 10,649 SNPs were selected based on their physical annotation.
Statistical analyses
Background characteristics and quality of lifeQoL scores of the selected KARMA women were
compared to a Swedish reference population.[31] The QoL scores on the 15 domains were
therefore transformed to standard scores based on the scores of an age-matched Swedish refer-
ence population. To compare, standard scores were calculated by dividing the difference be-
tween the mean scores of the KARMA women and the scores of the age-matched reference
population, by the standard deviations of the reference population. The value of the standard
scores can be interpreted according to Cohen’s effect size (d), where a score of<0.2 indicates a
small, 0.5–0.8 a moderate and>0.8 a large difference. Analyses were performed in SPSS 16.0.
Relating single nucleotide polymorphisms to quality of life Initially, possible covariables for
the relation between SNPs and QoL were identified. To do so, all background characteristics
(listed in Table 1) were related to each of the QoL-domains separately by means of regression
analyses. Background characteristics that were associated with QoL (p<0.10) were included as
covariables in the subsequent analyses. To control for population stratification [32], principal
components analysis (PCA) was performed by EIGENSTRAT V.4.2 (1,2). We visually in-
spected PCA plots for outliers in terms of ancestry from CEU (northern and western Europe)
clusters. Five principal components were retained after inspection of a Scree plot, and included
as covariables in subsequent analyses. For the main analyses, regression analyses were used to
study the association between SNPs and QoL, while controlling for covariables and the five
principal components. Analyses were performed for SNPs selected on functional and physical
annotation separately and run in the statistical program PLINK.[33] Bonferonni corrected
p-value was set at 3.76E-06 (0.05 divided by (2,663+10,649 SNPs)). For 10 of the 15 QoL-
domains the distribution of scores was non-normal. Scores on the cognitive functioning scale
were transformed using square root transformation [
p
(101-raw score)]. On the remaining
nine domains a large percentage of women (range from 66.6% to 92.0%) reported the maxi-
mum score on the functional scales and the minimum score on the symptom scales/items.
These domains were therefore dichotomized; minimum/maximum value versus the
remaining answers.
Gene-Based analyses Gene-based analyses were performed relating the combined effect of
10,649 SNPs (that were selected based on physical location) for each gene to QoL. Analyses
were performed for each of the QoL-domains separately, using the Versatile Gene-based Asso-
ciation Study (VEGAS) software.[34] This software package applies a test by using simulations
The Genetic Basis of Quality of Life: A Candidate Gene Approach
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Age in mean years (range)a 54.3 (22–88)
Educational levelb





Being on hormone replacement therapy (yes) 1709 (33.2)
Using painkillers (yes) 4931 (95.9)





Four or more 68 (1.3)
Lifestyle factors
Body mass index (BMI) as mean score (range)d 25.2 (17–52)
Using tobacco (yes) 684 (13.3)
Psychological factors
Stress in the last five yearse
Never stressed 275 (5.4)
Seldom stressed 1849 (36.4)
Often stressed 2379 (46.9)
Always stressed 571 (11.3)





Four or five 89 (1.7)
Hours of sleepf
5 hours or less 207 (4.4)
6 hours 1103 (23.2)
7 hours 2170 (45.7)
8 hours or more 1269 (26.7)
Note: Data is presented as frequencies (percentages) for 5,142 healthy women included in the KARMA
study. Age and body mass index are provided in mean (range).
a = information is missing for 1 participant;
b = information is missing for 14 participants;
c = High blood pressure and depression are the most common conditions;
d = for 17 participants information was unavailable;
e = for 68 participants no information was available;
f = information is missing for 393 participants.
doi:10.1371/journal.pone.0118292.t001
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from the multivariate normal distribution by incorporating information on a set of SNPs with-
in a gene while accounting for LD between SNPs. VEGAS uses HapMap populations to esti-
mate patterns of LD for each gene.[34] Statistical significance is assessed adaptively. In the first
step, 1000 simulations are run. If the empirical p-value is<0.01, another 10,000 simulations
are performed. If, the empirical p-value is<0.001, another 1,000,000 simulations are per-
formed. If an empirical p-value of 0 is reached, no more simulations will be performed.
Results
Background characteristics and quality of life
For 5,142 out of 68,334 KARMA women information on both QoL and genotype data was
available, and they were therefore included in this study. Women diagnosed with breast cancer
before entering KARMA were excluded. Characteristics of the participating women are pre-
sented in Table 1. Women’s scores on the QoL domains are presented in Table 2. Overall, the
KARMA women reported a good QoL as they appear to function well and report few symp-
toms. Although the selected KARMA women scored significantly (p<0.01) different on many
Table 2. Mean quality of life scores.
N = 5,142
EORTC QLQ-C30 DOMAINS
Global health/ quality of life 75.8 (22.2)
Functional scales
Physical functioning (highest QoL) 3427 (66.6)
Role functioning (highest QoL) 3825 (74.5)
Emotional functioning 76.1 (22.8)
Cognitive functioninga 87.8 (19.2)
Social functioning (highest QoL) 3826 (74.5)
Symptom scales/items
Fatigue 22.4 (20.8)




Appetite loss (highest QoL) 4648 (90.4)
Constipation (highest QoL) 4409 (85.8)
Diarrhea (highest QoL) 4556 (88.7)
Financial difficulties (highest QoL) 4725 (92.0)
Note: For global health/quality of life and the functional scales a higher score indicates a better quality of
life, whereas for the symptom scales/items a lower score indicates a better quality of life. For the
continuous variables (i.e. global health/quality of life; emotional functioning; cognitive functioning; fatigue;
pain; dyspnoea; and insomnia) mean scores (SD) are presented. For the dichotomized scales (i.e. physical
functioning; role functioning; social functioning; nausea and vomiting; appetite loss; constipation; diarrhea;
financial difficulties) frequencies and percentages for the category with the highest quality of life is
provided. Please note that for 6, 3, 10, 1, 0, 6, 5, 3, 2, 13, 4, 3, 2, 4, 7 participants respectively information
was missing.
a = cognitive functioning was transformed by using square root transformation [
p
(101-raw score)], ranging
from 1–10 with low scores having a better cognitive functioning. The transformed mean score and standard
deviation is 2.9 (2.4).
doi:10.1371/journal.pone.0118292.t002
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of the QoL-domains compared to the Swedish reference sample, differences had a small effect
size (Cohen’s d<0.3) (S1 Fig. Comparing quality of life scores of the KARMA women to a Swed-
ish reference sample).
Results of the identification of possible covariables, relating background characteristics to
each QoL-domain, are provided in S2 Table (S2 Table. The association between background
characteristics and quality of life using Wald Chi Square test-statistic). As expected, age was
positively related to mental QoL (e.g. emotional functioning) and negatively to physical QoL
(e.g. physical functioning). Overall, the number of medical conditions, stress during the last
five years, and the number of life stressors showed the strongest negative association, whereas
the number of hours of sleep had the strongest positive relation with the QoL domains.
Single nucleotide polymorphisms and genes related to quality of life
Results of the association study relating the SNPs selected by functional and physical annota-
tion to QoL, while controlling for possible covariables (S2 Table. The association between back-
ground characteristics and quality of life using Wald Chi Square test-statistic) are provided in
Table 3 and 4 respectively. None of the SNPs selected by functional annotation were signifi-
cantly related to QoL (Table 3). For SNPs selected based on their physical annotation, there
was no statistically significant relation between SNPs and QoL-domains (Table 4). The stron-
gest association was found between cognitive functioning and the top SNP rs1468951
(p = 1.21E-05, Bonferonni-corrected p-value = 3.76E-06) in the GSTZ1 gene (Table 4), inde-
pendent of background characteristics (i.e. age, using painkillers, number of medical condi-
tions, using hormone replacement therapy, level of stress in the last five years, number of life
stressors, and number of hours of sleep) and the five principal components (controlling for
population stratification). This top SNP was an imputed marker, which is in high LD with the
genotyped SNP rs1046428 (r2 = 0.99). A Manhattan plot of the relation between cognitive
functioning and SNPs based on their physical annotation was prepared using Haploview and is
displayed in (S2 Fig. Manhattan plot (p-values per chromosome) for the relation between cogni-
tive functioning and the SNPs found based on physical location for the selected candidate genes).
[35] The locus-specific association map centered at the top SNP rs1468951 showed low
p-values for several SNPs on the GSTZ1 gene, indicating a relation with cognitive functioning
(Fig. 1).[36] To examine the stability of the effect estimate, a sensitivity analysis was performed
by sequential omission of individual covariables (leave-one-out analysis). Results revealed that
the estimate of rs1468951 remained stable (data not shown).
Furthermore, results of the gene-based test VEGAS are provided in Table 5. The GSTZ1
gene (11 SNPs) was significantly associated with cognitive functioning (p = 2.60E-05). For the
other domains, none of the genes reached statistical significance after correction for multiple
testing. The genotype specific sample and effect sizes for the 11 GSTZ1 SNPs are provided in
S3 Table (S3 Table: The sample and effect sizes for the 11 SNPs in the GSTZ1 gene).
Identification of causal variants
To identify the causal variant or variants we used two distinct approaches. First, forward selec-
tion regression analyses using the step function in R, adjusted for all covariates and principal
components, was utilized. The full model included the genotypes of the 11 SNPs annotated to be
+-20kb of GSTZ1 and retained in the VEGAS gene-based analysis. Due to high LD structure in
the region a penalty term of five was used [37], with rs11845842 retained in the analysis. Second,
we used the ICSNPathway software [38], to explore the coding variant likely responsible for the
relation with cognitive functioning. Results showed one candidate causal SNP (rs1046428) and
three candidate causal pathways (‘nitrogen compound metabolic process’, ‘anine metabolic
The Genetic Basis of Quality of Life: A Candidate Gene Approach
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process’, ‘amino acid metabolic process’, ‘carboxylic acid metabolic process’, and ‘oxidoreductase
activity’). These results indicate the following hypothesis [rs1046428 (non-synonymous
coding)-> GSTZ1 -> nitrogen compound metabolic process’/‘anine metabolic process’/‘amino
acid metabolic process’/‘carboxylic acid metabolic process’/‘oxidoreductase activity’ pathways].
Both procedures identified different SNPs, which are in high LD with each other (r2 = 0.90), they
are thus probably tagging the same causal variant. Furthermore, rerunning the gene-based analy-
sis by excluding our top SNP rs1468951 and the eight GSTZ1 SNPs in high LD (r2>0.9) showed
thatGSTZ1 was no longer significantly related to cognitive functioning (p = 4.15E-02). This indi-
cates the cumulative effects in the LD block surrounding rs1468951 within the GSTZ1 gene.
Discussion
Overall, we found no relation between genetic variations and 14 out of 15 QoL-domains inves-
tigated in this study. For cognitive functioning variations in the GSTZ1 gene were statistically
significant, independent of background characteristics and population stratification.
There are various plausible reasons for the absence of associations between genetic varia-
tions and QoL in this study. It is likely that this is—at least in part—the result of limited
Table 3. Relation between quality of life and the single nucleotide polymorphisms selected by functional annotation (n = 2,663).
FUNCTIONAL ANNOTATION
top SNP Chr Position Minor/major MAF Beta (SE) p GENE
QUALITY OF LIFE
Global health/ QoL rs1603406 12 87887139 G/A 0.40 -1.31 (0.41) 1.52E-03 GLDC
Functional scales
Physical functioning rs10750403 11 128477472 C/T 0.45 0.15 (0.05) 1.36E-03 PRKACA
Role functioning rs12218712 10 24292743 A/T 0.31 0.18 (0.05) 1.18E-03 HLA-DRB1
Emotional functioning rs12415866 10 44686664 G/A 0.12 2.15 (0.60) 3.34E-04 RHBDF2
Cognitive functioninga rs17159612 7 84725413 C/T 0.24 -0.16 (0.05) 2.69E-03 SLC6A4
Social functioning rs1380162 4 119970203 A/G 0.33 0.16 (0.06) 4.71E-03 HSN2
Symptom scales/items
Fatigue rs1603406 12 87887139 G/A 0.40 1.46 (0.42) 5.56E-04 GLDC
Nausea and vomiting rs1560580 2 137745374 A/G 0.45 -0.26 (0.07) 1.24E-04 RHBDF2
Pain rs10150965 14 29018461 G/C 0.41 1.82 (0.52) 5.02E-04 WNK1
Dyspnoea rs1407818 1 192561712 G/A 0.19 -2.21 (0.68) 1.18E-03 MYB
Insomnia rs1185701 1 156419617 C/G 0.14 -3.24 (0.79) 4.46E-05 LIPG
Apetite loss rs10883690 10 83488792 G/T 0.29 -0.28 (0.09) 1.34E-03 PRKACA
Constipation rs1408808 9 12542187 C/G 0.36 0.20 (0.06) 1.43E-03 UMPS/DRD4
Diarrhoea rs11848780 14 34169150 A/G 0.13 -0.34 (0.11) 1.29E-03 CD19/MIF/GSTP1
Financial difficulties rs13160478 5 118082740 G/A 0.11 -0.51 (0.16) 1.04E-03 CASP8
Note: For the 139 candidate genes, 2,663 SNPs were selected based on functional annotation. Bonferonni p-value = 3.76E-06 (0.05/2,663+10,649
SNPs). For the continuous variables (i.e. global health/quality of life; emotional functioning; cognitive functioning; fatigue; pain; dyspnoea; and insomnia)
linear regressions were performed. For the dichotomized variables (i.e. physical functioning; role functioning; social functioning; nausea and vomiting;
appetite loss; constipation; diarrhea; financial difficulties) we used logistic regression analyses. Chr = chromosome; Position = position of the
chromosome; Minor/major = minor and major alleles based on forward strand and minor allele frequencies in Europeans; MAF = minor allele frequency
over all European controls in iCOGS; Beta = beta value for the minor allele relative to the major allele; SE = standard error; p = p-value.
a = cognitive functioning was transformed by using square root transformation [
p
(101-raw score)] ranging from 1–10, with low scores having a better
cognitive functioning, therefore the direction of the relation is reversed.
doi:10.1371/journal.pone.0118292.t003
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variation in QoL, due to our healthy female sample. Second, adoption of a candidate gene ap-
proach may have resulted in a too limited selection of genes. Furthermore, genotyping was per-
formed by using the iCOGS chip, which was originally built to identify the genetic risk for
breast, ovarian and prostate cancer. Although, after imputation, the iCOGS chip covers 60% of
what an Illumnia HumanHap550 chip covers, the dispersion over the entire genome may still
be skewed. Third, for complex phenotypes a genetic predisposition may be the result of several
genes working in concert or the effect of an entire pathway.
The strongest association (p = 1.21E-05, Bonferonni-corrected p-value = 3.76E-06) was
found between cognitive functioning and the top SNP rs1468951 in the GSTZ1 gene, while
controlling for background characteristics and population stratification. The imputed marker
is in almost perfect LD (r2 = 0.99) with the genotyped SNP rs1046428 the latter of which has
been annotated in dbSNP as a non-synonymous missense mutation (M [Met]) T [Thr]),
(S3 Fig. Predicted chromatin state, sequence conservation across mammals, and effect on regula-
tory motifs of rs1468951 and variants with r2 > = 0.8).[39] Mining the ENCODE [40] data via
HaploReg[39], the intronic variant rs1468951 was predicted to be in DNase hypersensitivity re-
gions in numerous cell lines; and altering predicted relative affinity of two transcription factors
Table 4. Relation between quality of life and the single nucleotide polymorphisms selected by physical annotation (n = 10,649).
PHYSICAL ANNOTATION
top SNP Chr Position Minor/ major MAF Beta (SE) p GENE
QUALITY OF LIFE
Global health/ QoL rs3783547 2 113533339 G/A 0.37 -1.43 (0.42) 6.66E-04 IL1A
Functional scales
Physical functioning rs16080 7 24350966 T/C 0.08 0.35 (0.10) 3.28E-04 NPY
Role functioning rs3889728 1 23084881 C/T 0.25 -0.22 (0.06) 1.14E-04 AGT
Emotional functioning rs2475376 10 96712400 A/G 0.15 2.04 (0.54) 1.63E-04 CYP2C9
Cognitive functioninga rs1468951 14 77793487 A/C 0.18 0.25 (0.06) 1.21E-05 GSTZ1
Social functioning rs57758950 8 105453992 T/C 0.13 -0.32 (0.07) 1.63E-05 DPYS
Symptom scales/items
Fatigue rs2813555 6 152442582 A/G 0.20 1.76 (0.52) 7.56E-04 ESR1
Nausea and vomiting rs4950025 1 97717279 C/A 0.05 -0.82 (0.19) 1.95E-05 DPYD
Pain rs35258421 4 142545105 A/G 0.18 2.29 (0.66) 4.86E-04 IL15
Dyspnoea rs7648614 3 123328980 T/C 0.08 -3.85 (1.08) 3.59E-04 MYLK
Insomnia rs4298 17 61557200 C/G 0.05 4.09 (1.23) 8.61E-04 ACE
Apetite loss rs6062900 20 61980125 G/C 0.12 -0.43 (0.12) 6.03E-04 CHRNA4
Constipation rs324969 7 34791852 G/A 0.48 -0.20 (0.06) 9.11E-04 NPSR1
Diarrhoea rs748190 10 131519274 G/A 0.46 0.26 (0.07) 2.12E-04 MGMT
Financial difficulties rs496338 10 131412605 A/T 0.12 -0.59 (0.15) 8.86E-05 MGMT
Note: For the 139 candidate genes, 10,649 SNPs were selected based on physical annotation (build 37). Bonferonni corrected p-value = 3.76E-06
(0.05/2,663+10,649 SNPs). For the continuous variables (i.e. global health/quality of life; emotional functioning; cognitive functioning; fatigue; pain;
dyspnoea; and insomnia) linear regressions were performed. For the dichotomized variables (i.e. physical functioning; role functioning; social functioning;
nausea and vomiting; appetite loss; constipation; diarrhea; financial difficulties) we used logistic regression analyses. Chr = chromosome;
Position = position of the chromosome; Minor/major = minor and major alleles based on forward strand and minor allele frequencies in Europeans;
MAF = minor allele frequency over all European controls in iCOGS; Beta = beta value for the minor allele relative to the major allele; SE = standard error;
p = p-value.
a = cognitive functioning was transformed by using square root transformation [
p
(101-raw score)] ranging from 1–10, with low scores having a better
cognitive functioning, therefore the direction of the relation is reversed.
doi:10.1371/journal.pone.0118292.t004
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Fig 1. Locus-specific association map generated from genotyped SNPs in the chromosome 14, centered at rs1468951 for cognitive functioning.
Note: Vertical axis is the—log10 of the p-value, the horizontal axis is the chromosomal position. Each dot represents a SNP tested for association with
cognitive functioning. Linkage disequilibrium (LD) between the most significant SNP, listed at the top of the plot, and the other SNPs in the plot is shown by
the r2 legend. Locus zoom software was used to prepare this figure.[36]
doi:10.1371/journal.pone.0118292.g001
Table 5. Gene-based test for 139 candidate genes using the single nucleotide polymorphisms selected by physical location.
QUALITY OF LIFE Chr Gene nSNPs Start pos End pos p
Global health/ QoL 5 IL12B 57 158674368 158690059 1.20E-02
Functional scales
Physical functioning 7 NPY 5 24290333 24298002 8.38E-04
Role functioning 1 AGT 51 228904891 228916959 5.74E-04
Emotional functioning 5 NR3C1 12 142637688 142795270 6.00E-03
Cognitive functioning 14 GSTZ1 11 76857106 76867693 2.60E-05*
Social functioning 10 MGMT 114 131155455 131455358 4.81E-03
Symptom scales/items
Fatigue 12 NR3C1 12 142637688 142795270 1.31E-02
Nausea and vomiting 12 GNB3 1 6819635 6826818 1.13E-03
Pain 1 PER3 51 7767349 7827824 1.21E-02
Dyspnoea 20 GNAS 7 56848189 56919645 5.53E-03
Insomnia 12 AVPR1A 35 61826482 61832857 6.32E-03
Apetite loss 20 CHRNA4 2 61445108 61463139 1.91E-03
Constipation 3 UMPS 56 125931902 125946730 9.73E-03
Diarrhoea 10 BTRC 58 103103814 103307060 1.75E-03
Financial difficulties 7 NPY 5 24290333 24298002 1.49E-03
Note: * p < Bonferonni corrected p-value of 3.60E-04 (0.05/139 candidate genes). Chr = Chromosome; nSNPs = number of SNPs; Test stat = test
statistic; p = p-value.
doi:10.1371/journal.pone.0118292.t005
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(EBF and FXR) (S4 Fig. Epigenetic road map for rs1468951 effect on regulatory motifs of
rs1468951 and variants with r2 > = 0.8). Mining the RoadMap [41] data predicts rs1468951 to
lie in regions in which modification of histone proteins is suggestive in several different cell
types (LIV.A, PFM.3 and PFF.2) (S4 Fig. Epigenetic road map for rs1468951 effect on regulatory
motifs of rs1468951 and variants with r2 > = 0.8). Results of the association between cognitive
functioning and the top SNP (rs1468951) without adjusting for background characteristics
showed that the relation was not significant [data not shown]. We opted for the inclusion of
the covariables based on both literature and the significant findings in the preliminary
analyses.[42–45]
In addition, we found that the combined effect of the 11 SNPs within the GSTZ1 gene were
significantly related to cognitive functioning independent of background characteristics, indi-
cating that the multiple smaller effects of the 11 individual GSTZ1 SNPs seem to be working in
concert. This finding is in line with the general understanding that cognitive functioning
(e.g. IQ, memory, and concentration) is heritable, and in concordance with the current knowl-
edge of the GSTZ1 gene. GSTZ1 encodes multifunctional enzymes important in detoxification
and several drugs by conjugation with glutathione. One of these enzymes is maleylacetoacetate
isomerase (MAAI) which is involved in the catabolism of phenylalanine and tyrosine.[23,46]
Defects in the tyrosine enzyme may lead to severe metabolic disorders including tyrosinaemia
which leads to mental retardation and cognitive problems.[47] In experimental studies the ad-
ministration of tyrosine to individuals under stress leads to improved cognitive functioning, in-
cluding memory tasks.[48] The physiological basis of this beneficial effect of tyrosine is
attributed to its role as precursor for the synthesis of dopamine, which is a major neurotrans-
mitter widely distributed within the brain.[48,49] It is well-known that dopaminergic neuro-
transmission in the prefrontal cortex contributes to individual differences following a
non-linear relation, a so-called reversed U-form.[50] Next to the catabolization of tyrosine into
dopamine, GSTZ1 also contributes to the equilibrium between dopamine and its neurotoxic
metabolites via the glutathione redox cycle.[51] Hypothesized is that dopamine and its metabo-
lites have cytotoxic actions on neurons, thereby negatively impacting cognitive functioning,
contributing to the U-shaped relation.[52] In a first study relating GSTZ1 to cognitive func-
tioning among 64–68 aged 470 Scottish community volunteers, a significant association with
SNP-1002 G>A was found. A-carriers showed a significantly lower mean score on cognitive
functioning, supporting the hypothesis that dopamine disposal pathways may have a negative
impact on cognitive functioning.[52]
Limitations and strengths
There are some noteworthy limitations to this study. As already mentioned, genotyping was
performed by using the iCOGS chip, which was originally designed to identify risk factors for
breast, ovarian, and prostate cancer. For the gene based analyses we used the VEGAS approach
which utilizes HapMap populations to estimate patterns of LD for each gene. In this study, im-
putations of SNPs were performed by using the 1000 genome reference panel. HapMap has no
complete coverage of the number of SNPs per candidate gene as compared to the 1000 genome
reference panel.[53] Second, other factors that were not measured could also impact variation
in QoL either directly or via genes. For a detailed description of possible relations between bio-
logical factors (including genetic markers), background characteristics, and QoL, see the
adapted theoretical model of Wilson and Cleary.[20] In addition it is worth mentioning, that
we measured subjective cognitive functioning which was assessed by two self-reported items
concerning memory and concentration. This two-item scale can be considered limited, howev-
er, it has been found to yield high levels of reliability and validity.[26] Furthermore, there is a
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risk for reporting false positives given the number of tests; for each QoL-domain we related
13,312 SNPs and 139 genes. Finally, this candidate gene study is based on only one study,
therefore further validation in independent datasets would be required to confirm the associa-
tion between GSTZ1 and subjective cognitive functioning. Since this is a novel area of research
the number of studies collecting both genetic and QoL-information are scarce. To the best of
our knowledge, no external data are currently available that combine subjective cognitive func-
tioning as assessed with the EORTC QLQ-C30 and genetic data. Since an increasing number of
studies are now embarking on the assessment of QoL and genetic data, validation of these data
will be possible in the future.
It is important to note that there is controversy in what constitutes QoL. Although QoL can
be described as a uni-dimensional concept, we view it as multifactorial consisting of a person’s
perception of several domains such as fatigue, physical, emotional, cognitive, and social func-
tioning. One can hypothesize that the more ‘biological’ domains, such as physical and cognitive
functioning may have a stronger genetic basis, than for example social functioning. Neverthe-
less, a recent review reported heritability for social functioning.[54] In our study, there was no
significant relation between social functioning and genetic markers. Various possible reasons
for this lack of association are provided at the beginning of the discussion. Contrary to our
findings, another study examining the relation between genetics and cognitive functioning
found a significant association with rs1046428.[55] The most likely explanation for this dis-
crepancy is the difference in measuring cognitive functioning. Where we measured cognitive
functioning by self-report examining perceived memory function and concentration, Harris
et al. used tasks to examine general mental ability, non-verbal reasoning, verbal fluency and
logical memory.[55] These two studies thus examine distinct, albeit related concepts, thereby
impeding their comparison.
We would also like to stress the strengths. This is the first study relating QoL to genes in a
large sample of healthy females, while statistically controlling for background characteristics
including self-reported chronic diseases thereby minimizing the impact of medical conditions.
Moreover, the used iCOGS chip has a fairly comprehensive genetic coverage. Furthermore, the
included sample of healthy women is representative for the general Swedish population in
terms of QoL, increasing generalizability of the results.
Conclusion and future directions
In conclusion, the involvement of GSTZ1 in cognitive functioning underscores its heritability
which is likely the result of differences in the dopamine pathway. Findings support the hypoth-
esis that dopamine can have negative effects via the neurotoxic by-products.[51] The obvious
next step is to replicate the association between cognitive functioning and variations in the
GSTZ1 gene to ensure it is not a chance finding. Although needed, validation is challenging as
cognitive functioning is measured in varying ways. In this study measurement entailed two
questions tapping into memory and concentration as specific aspects of cognitive functioning.
For future research relating various QoL-domains to genetic markers, a candidate gene ap-
proach may be too limited, possibly missing valuable associated genes. Therefore we also opt
for a whole genome approach in future studies. Additional research is needed as findings will
be valuable in clinical settings. Identified genes can be used as indicators for those who are sus-
ceptible to impairments in their QoL. This is particularly useful information for individuals
who are experiencing high levels of stress, such as when being diagnosed with or treated for a
life-threatening disease. Clinicians may be guided by this information, opting for treatments
with the smallest negative impact on QoL and providing additional support to those patients
who need it.
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Supporting Information
S1 Table. The list of 139 candidate genes, which are all related to at least one QoL-domain.
(XLS)
S2 Table. The association between background characteristics and quality of life using
Wald Chi Square test-statistic.
(DOCX)
S3 Table. The sample and effect sizes for the 11 SNPs in the GSTZ1 gene.
(DOCX)
S1 Fig. Comparing quality of life scores of the KARMAwomen to a Swedish reference sample.
[31]. Note: QL = global health/quality of life; PF = physical functioning; RF = role functioning;
CF = cognitive functioning; EF = emotional functioning; SF = social functioning; PA = pain;
FA = fatigue; NV = nausea and vomiting; SL = insomnia; DY = dyspnoea; AP = appetite loss;
CO = constipation; DI = diarrhea; FI = financial difficulties p<0.01. For example, KARMA
women reported better physical functioning, yet more sleeping problems than the Swedish refer-
ence sample.[31]
(TIF)
S2 Fig. Manhattan plot (p-values per chromosome) for the relation between cognitive func-
tioning and the SNPs found based on physical location for the selected candidate genes.
Note: The Bonferonni corrected value is—log10(3.76E-06) = 5.42.This Manhattan plot was
prepared using Haploview.[35]
(TIF)
S3 Fig. Predicted chromatin state, sequence conservation across mammals, and effect on reg-
ulatory motifs of rs1468951 and variants with r2> = 0.8.Note: This figure is a print shot of
the haploreg database, see http://www.broadinstitute.org/mammals/haploreg/haploreg.php.[39]
(TIF)
S4 Fig. Epigenetic road map for rs1468951 effect on regulatory motifs of rs1468951 and
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